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The term 'hepatic encephalopathy' refers to a spectrum of neuropsychiatric changes occurring in people with liver
insufficiency or portal-systemic shunting (AASLD and EASL Guideline 2014a; AASLD and EASL Guideline 2014b).
The term 'minimal' hepatic encephalopathy (in the older literature 'subclinical' or 'latent') refers to people with cirrhosis
who are ‘clinically normal’, but who show abnormalities in neuropsychometric or neurophysiological performance (Ferenci
2002). Changes in mental state range from subtle alterations in cognitive function to profound alterations in
consciousness leading to deep coma with decerebrate posturing. Clinically apparent or 'overt' hepatic
encephalopathy manifests as a neuropsychiatric syndrome encompassing a wide spectrum of mental and motor
disorders (Weissenborn 1998; Ferenci 2002). Events such as gastrointestinal bleeding, infection, and alcohol misuse can
trigger this so-called 'acute' or 'episodic' hepatic encephalopathy. Fifty per cent of instances occur with no obvious
cause. After an episode, people may return to their baseline neuropsychiatric status or show clinical evidence of
impairment (Bajaj 2010). Less frequently, people present with persistent neuropsychiatric abnormalities, often due to
extensive spontaneous portal-systemic shunting or after insertion of a transjugular intrahepatic portosystemic shunt
(TIPS). Patients may experience asterixis (flapping tremor) or a variety of other changes in motor function (Victor 1965; 
Weissenborn 1998; Cadranel 2001). Overt hepatic encephalopathy is also associated with impaired psychometric
performance (Schomerus 1998), disturbed neurophysiological function (Chu 1997), altered cerebral
neurochemical/neurotransmitter homeostasis (Taylor-Robinson 1994), reductions in global and regional cerebral
blood flow and metabolism (O'Carroll 1991), and changes in cerebral fluid homeostasis (Haussinger 2000). For most people,
the degree of impairment increases as the clinical condition worsens.
Diagnosing hepatic encephalopathy
The diagnosis of hepatic encephalopathy may present no problems, but without the background information and
an obvious precipitating event, hepatic encephalopathy may go unrecognised. We have no gold standard for the
diagnosis (Montagnese 2004; AASLD and EASL Guideline 2014a; AASLD and EASL Guideline 2014b), but
rather techniques which we can use singly or in combination. The diagnosis of overt hepatic encephalopathy
requires a detailed neuropsychiatric history and examination (Montagnese 2004) with particular attention paid to
changes in memory, concentration, cognition, and consciousness. Clinicians and researchers often use the West
Haven criteria to grade mental state (Conn 1977) and the Glasgow Coma Score to grade the level of consciousness
(Teasdale 1974). The neurological examination looks for evidence of subtle motor abnormalities and excludes
other potential causes of neuropsychiatric abnormalities including neurological disorders and metabolic
abnormalities. People with hepatic encephalopathy have impaired psychometric performance (Montagnese 2004; Randolph
2009). Those with minimal hepatic encephalopathy show deficits in attention, visuo-spatial abilities, fine motor
skills, and memory, while their other cognitive functions are relatively well preserved. People with overt hepatic
encephalopathy show additional disturbances in psychomotor speed, executive function, and concentration.
Psychometric test batteries to assess cognitive function form part of the evaluation. The Psychometric Hepatic
Encephalopathy Score has a high specificity for the diagnosis (Schomerus 1998; Weissenborn 2001). The test
employs five paper and pencil tests to assess attention, visual perception, and visuo-constructive abilities. Test scores
have to be normalised to take account of factors such as age, sex, and educational level. At present, normative
databases are available in Germany, Italy, Denmark, Spain, Mexico, Korea, India, and Great Britain. People with
hepatic encephalopathy may also have neurophysiological abnormalities (Guérit 2009). The electroencephalogram
may show progressive slowing of the background activity and abnormal wave morphology. Other potential diagnostic
techniques include the Critical Flicker Fusion Frequency (Kircheis 2002) and the Inhibitory Control Test (Bajaj 2008). The
tests need further validation.
Description of the intervention
Ammonia plays a key role in the development of hepatic encephalopathy (Butterworth 2014). Ammonia scavengers are
agents developed for the reduction of blood ammonia concentration used for the treatment of children with urea cycle
disorders (Berry 2014). The available scavenging drugs (Table 1) tested for people with hepatic encephalopathy
include AST-120 (Spherical Carbon Adsorbent), glycerol phenylbutyrate, and ornithine phenylacetate, which is a
combination of L-ornithine and phenylacetate (Sushma 1992; Efrati 2000; Jalan 2007; Bosoi 2011; Misel 2013; Ventura-Cots
2013; Wu 2014; Rahimi 2016). The adverse events associated with the use of these drugs are mainly gastrointestinal
and include diarrhoea, constipation, dry mouth, and changes in appetite (Lee 2010).
How the intervention might work
The pathogenesis of hepatic encephalopathy is complex. The disease is multifactorial with accumulation of
toxins, chronic inflammation, and ion abnormalities. Increased levels of ammonia play a key role (Butterworth 2013; 
Butterworth 2014). A number of interventions for the management of hepatic encephalopathy aim at decreasing the
absorption of ammonia through a reduction in intestinal transit or altering the microbiome. Current guidelines
recommend nonabsorbable disaccharides as the treatment of choice (AASLD and EASL Guideline 2014a; AASLD and
EASL Guideline 2014b; Gluud 2016a; Gluud 2016b). The antibiotic rifaximin, which is a poorly absorbed antibiotic, is
used as an add-on therapy for the prevention of recurrent episodes (Bass 2010). Ammonia scavengers are a new
potential treatment option (McGuire 2010; Rose 2012; Jover-Cobos 2013). These drugs primarily work by increasing
the excretion of ammonia through alternative pathways for the metabolism of glutamine (Table 1).
Why it is important to do this review
Hepatic encephalopathy is a serious complication to cirrhosis and puts a considerable burden on the people
affected, their families, and healthcare systems (Stepanova 2012). Ammonia scavenging agents may be effective as
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an alternative or add-on intervention, as shown by their ability to reduce ammonia levels. In spite of their theoretical
effect, randomised clinical trials (RCTs) are needed to determine the clinical effects (McGuire 2010; Rockey 2014). At
present, there are only a few published RCTs, but ongoing and planned RCTs are expected to increase the strength of
the evidence in the near future (Bajaj 2013; Pockros 2009; Sherker 2009; Rockey 2014; NCT01966419; NCT00558038). We
therefore decided to conduct this systematic review evaluating the effect of ammonia scavenging agents for people with
cirrhosis and hepatic encephalopathy.
Objectives 
To evaluate the benefits and harms of ammonia scavenging agents versus placebo, no intervention, or other active
interventions for people with cirrhosis and hepatic encephalopathy.
Methods 
Criteria for considering studies for this review 
Types of studies 
We will include randomised clinical trials (RCTs), irrespective of blinding, language, or publication status. We will include
quasi-randomised studies and observational studies in the analyses of adverse events.
Types of participants 
We will include RCTs evaluating people with cirrhosis and hepatic encephalopathy regardless of age or underlying aetiology.
We will include RCTs evaluating prevention or treatment of hepatic encephalopathy (overt or minimal).
Types of interventions 
We will evaluate ammonia scavenging agents (including glycerol phenylbutyrate, ornithine phenylacetate, and spherical
carbon adsorbents also known as AST-120) versus placebo or no intervention or interventions with a potential effect on
hepatic encephalopathy (such as non-absorbable disaccharides or antibiotics). Co-interventions administered equally to the
intervention and control groups are allowed.
We will not include studies of L-ornithine L-aspartate in this review due to overlap with another Cochrane review (Stokes
2016).
Types of outcome measures 
We will assess all outcomes at the maximum duration of follow-up (Gluud 2016c).
Primary outcomes
Mortality.1.
Hepatic encephalopathy. We will assess the outcome using the primary investigators' overall assessment of: i) number of2.
participants who developed hepatic encephalopathy, and ii) number of participants without a clinically-relevant
improvement in hepatic encephalopathy.
Serious adverse events: defined as any untoward medical occurrence that led to death, were life threatening, or3.
required hospitalisation, or prolongation of hospitalisation (ICH-GCP). We will analyse these as a composite
outcome (Gluud 2016c).
Secondary outcomes
Quality of life.1.
Non-serious adverse events (defined as all adverse events that do no fulfil the criteria listed under serious adverse2.
events).
Liver-related mortality.3.
Exploratory outcomes
Blood ammonia levels.1.
Number Connection Test results.2.
Search methods for identification of studies 
Electronic searches 
We will search The Cochrane Hepato-Biliary Group Controlled Trials Register (Gluud 2016c), the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE, Embase, and Science Citation Index Expanded. We will prepare the search
strategies in collaboration with the Information Specialist of the Cochrane Hepato-Biliary Group. Preliminary search
strategies with the expected time spans of the searches are given in Appendix 1.
Searching other resources 
We will scan reference lists of relevant articles and conference proceedings (from the annual meetings of
the American Association for the Study of Liver Diseases and the European Association for the Study of
the Liver) and write to authors of trials and reviews on ammonia scavenging agents and pharmaceutical
companies. We will also search online trial registries such as ClinicalTrial.gov (clinicaltrials.gov/),
European Medicines Agency (EMA) (www.ema.europa.eu/ema/), WHO International Clinical Trial Registry
Platform (www.who.int/ictrp), and the Food and Drug Administration (FDA) (www.fda.gov), as well as pharmaceutical
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company sources for ongoing or unpublished trials.
Data collection and analysis 
We will use the Cochrane Hepato-Biliary Group module (Gluud 2016c) and follow the Cochrane Handbook for Reviews of
Interventions (Higgins 2011a) and the Methodological Expectations of Cochrane Intervention Reviews (MECIR)
guidelines (MECIR 2014).
Selection of studies 
All authors will participate in the identification and selection of included studies. Harry Zacharias and Antony
Zacharias will determine suitability for inclusion, outlined in 'Criteria for considering studies for this review', by screening
study titles and abstracts. We will retrieve the full texts of potentially eligible references and list included RCTs and excluded
RCTs and studies with the reason for exclusion. For trials reported in more than one publication, we will select the paper
reporting the longest duration of follow-up as the primary reference. We will list details of all included trials in summary tables
and list all excluded studies with the reason for their exclusion.
Data extraction and management 
Two review authors (Harry Zacharias and Antony Zacharias) will extract data from included trials. Disagreements will be
solved through discussion. A third author (Marsha Y Morgan or Lise L Gluud) will act as ombudsman.
We will write to the primary investigators for additional unpublished information not contained in the trial reports. We will
gather information about the following:
Trial: year and language of publication status; inclusion period; country; number of clinical sites; setting (inpatient or
outpatient). Intervention: dose and duration of experimental and control intervention(s); co-interventions. Participants:
characteristics (number/percent) of participants (inclusion criteria, age, sex, aetiology, proportion with alcoholic liver disease,
proportion with viral hepatitis B/C); assessment of hepatic encephalopathy. Outcomes: outcomes in the trial including
definitions used in the assessment and duration of follow up; Number of participants included in the assessment of outcomes
(number of losses to follow-up/withdrawals); outcomes included in the meta-analyses.
Assessment of risk of bias in included studies
We will assess bias control using the domains described in the Cochrane Hepato-Biliary Group Module (Gluud 2016c
), and classify the risk of bias for separate domains as high, unclear, or low (Higgins 2011a; Higgins 2011b).
Allocation sequence generation
Low risk of bias: sequence generation achieved using computer random number generation or a random number table.
Drawing lots, tossing a coin, shuffling cards, or throwing dice are adequate if performed by an independent person, but not
otherwise.
Unclear risk of bias: not described.
High risk of bias: the sequence generation method was not random.
Allocation concealment
Low risk of bias: allocation by a central and independent randomisation unit, administration of coded, identical drug
containers/vials or sequentially-numbered, opaque, sealed envelopes.
Unclear risk of bias: not described.
High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.
Blinding of participants and personnel
Low risk of bias: Any of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is
not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it is unlikely
that the blinding could have been broken.
Unclear risk of bias: Any of the following: insufficient information to permit judgement of ‘low risk’ or ‘high risk’; or the trial
did not address this outcome.
High risk of bias: Any of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack
of blinding; or blinding of key study participants and personnel attempted, but likely that the blinding could have been
broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of outcome assessors
Low risk of bias: Any of the following: no blinding of outcome assessment, but the review authors judge that the outcome
measurement is not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and unlikely
that the blinding could have been broken.
Unclear risk of bias: Any of the following: insufficient information to permit judgement of ‘Low risk’ or ‘High risk’; or the trial
did not address this outcome.
High risk of bias: Any of the following: no blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; or blinding of outcome assessment, but likely that the blinding could have been broken, and
the outcome measurement is likely to be influenced by lack of blinding.
Incomplete outcome data
Low risk of bias: missing data unlikely to make treatment effects depart from plausible values. The investigators used
Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy
4 / 13
sufficient methods, such as intention-to-treat analyses with multiple imputations or carry-forward analyses to handle
missing data.
Unclear risk of bias: insufficient information.
High risk of bias: the results were likely to be biased due to missing data.
Selective outcome reporting
Low risk of bias: the trial reported clinically-relevant outcomes (mortality, hepatic encephalopathy, and serious adverse
events). If we had access to the original trial protocol, the outcomes selected were those called for in that protocol. If we
obtained information from a trial registry (such as www.clinicaltrials.gov), we only used that information if the investigators
registered the trial before inclusion of the first participant.
Unclear risk of bias: not all predefined outcomes were reported fully, or it was unclear whether data on these outcomes
were recorded or not.
High risk of bias: one or more predefined outcomes were not reported.
For-profit bias
Low risk of bias: the trial appears to be free of industry sponsorship or other type of for-profit support.
Unclear risk of bias: insufficient information about support or sponsorship.
High risk of bias: the trial received funding or other support from a pharmaceutical company.
Other bias
Low risk of bias: the trial appeared to be free of other biases including: medicinal dosing problems or follow-up (as defined
below).
Unclear risk of bias: the trial may or may not have been free of other issues that could put it at risk of bias.
High risk of bias: there were other factors in the trial that could put it at risk of bias such as the administration of
inappropriate treatments being given to the controls (e.g. an inappropriate dose) or follow-up (e.g. the trial included
different follow-up schedules for participants in the allocation groups).
Overall bias assessment
Low risk of bias: all domains were classified as low risk of bias using the definitions described above.
High risk of bias: one or more of the bias domains were classified as unclear or high risk of bias.
Measures of treatment effect
We will use risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, both with 95%
confidence intervals (CI). For outcomes suggesting that the interventions have a beneficial or harmful effect, we will calculate
the number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful
outcome (NNTH) based on the risk difference (RD) as 1/RD.
Unit of analysis issues 
We will include data from the first treatment period of cross-over trials in our primary analyses (Higgins 2011a).
Dealing with missing data
We will collect data on all participants randomised, to allow intention-to-treat analyses including all participants
irrespective of compliance or follow-up. We will perform a worst-case scenario analysis to evaluate the influence of
missing data using simple imputation of missing values (Higgins 2008). In the worst-case scenario analysis, we will count all
participants with missing outcomes as treatment failures. We will also conduct an extreme worst-case scenario analysis with
missing outcome data counted as failures in the intervention group and successes in the control group.
Assessment of heterogeneity 
We will express heterogeneity as I2 values using the following thresholds: 0% to 40% (unimportant), 40% to 60% (moderate),
60% to 80% (substantial), and > 80% (considerable). We will include the information in the 'Summary of findings' tables.
Assessment of reporting biases
We will evaluate reporting bias based on the definition and reporting of key outcomes (the most clinically relevant) and
by comparing protocols, online trial registrations, and trial publications. For meta-analyses with at least 10 trials, we will
evaluate the risk of small study effects based on Egger's test for continuous outcomes (Egger 1997) and Harbord's
test for dichotomous outcomes (Harbord 2006). The Egger's test performs a linear regression of the intervention effect
estimates on their standard errors, weighting by 1/(variance of the intervention effect). The Harbord test regresses Z/sqrt(V)
against sqrt(V), where Z is the efficient score and V is Fisher's information (the variance of Z under the null hypothesis).
Data synthesis
We will perform the analysis in Review Manager (RevMan 2014), STATA 14 (Stata 2015), and Trial Sequential Analysis
(TSA 2011).
Meta-analyses
We will analyse ammonia scavenger agents separately and plan to conduct fixed-effect and random-effects meta-
analyses (Higgins 2011a). If the estimates of the random-effects and fixed-effect meta-analyses are similar, then we will
assume that any small-study effects have little effect on the intervention effect estimate. If the random-effects estimate is
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more beneficial, we will re-evaluate whether it is reasonable to conclude that the intervention was more effective in the
smaller studies. If the larger studies tend to be those conducted with greater methodological rigour, or conducted in
circumstances more typical of the use of the intervention in practice, then we will report the results of meta-analyses
restricted to the larger, more rigorous studies. Based on the expected clinical heterogeneity, we expect that a number of
analyses will display statistical between-trial heterogeneity (I2 > 0%). For random-effects models, precision will decrease with
increasing heterogeneity and confidence intervals will widen correspondingly. We therefore expect that the random-effects
model will give the most conservative (and a more correct) estimate of the intervention effect. Accordingly, we plan to report
the results of our analyses based on random-effects meta-analyses.
Trial Sequential Analysis
We plan to perform Trial Sequential Analyses for meta-analyses of our primary outcomes (Wetterslev 2008; TSA 2011; 
Higgins 2011b). We will define the required information size as the number of participants needed to detect or reject
an intervention effect estimate, based on the event proportion in the control group and the diversity of the meta-
analysis. We will define firm evidence as being established if the Z-curve crosses the trial sequential monitoring
boundaries for benefit, harm, or futility before reaching the required information size. Based on previous evidence (AASLD
and EASL Guideline 2014a; AASLD and EASL Guideline 2014b), we will conduct the analyses with alpha 5%, power 80%,
and the Relative Risk Reduction/control event rate to 15%/15% (mortality), 25%/35% (hepatic encephalopathy), and
15%/20% (serious adverse events).
Subgroup analysis and investigation of heterogeneity 
We plan to perform the following subgroup analyses:
bias control;
type of encephalopathy;
aetiology of liver disease (alcohol or hepatitis).
Sensitivity analysis
We will perform sensitivity analyses to evaluate publication status, and language, and conduct a worst-case scenario
analysis as described above.
'Summary of findings' table
We will use the GRADE system (GradePro 2015) to evaluate the quality of the evidence for all outcomes reported in the
review considering the within-study risk of bias (methodological quality), indirectness of evidence, heterogeneity, imprecision
of effect estimate, and risk of publication bias.
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Ammonia
scavenger
Appearance Dose tested in
people with cirrhosis
Mechanism of action
Spherical carbon
adsorbent
(AST-120)
Charcoal
powder
Orally administered
powder (sachets),
two grams three
times daily
Non-absorbable carbon microsphere (0.2 to 0.4 mm in diameter)
adsorbent, which is not degraded in the gastrointestinal lumen.
Glycerol
phenylbutyrate
Liquid Administered orally,
six ml twice daily for
16 weeks
Prodrug of sodium phenylbutyrate. In the body, glutamine synthetase
facilitates the formation of glutamine from glutamate and ammonia.
Glycerol phenylbutyrate leads to formation of phenylacetylglutamine
from phenylacetate and glutamine. The compound is excreted in the
urine. The effect of the drug is therefore increased excretion of
ammonia.
Ornithine
phenylacetate
Crystalline
salt
Administered as
intravenous infusion
10 g/24 h (0.42 g/h)
Reduces ammonia through two pathways: i) L-ornithine acts as a
substrate for the synthesis of glutamine from ammonia in skeletal
muscle, and ii) phenylacetate and glutamine combines to form
phenylacetylglutamine, which is excreted in the urine.
Sodium
benzoate*
Crystalline
powder
Not applicable Forms water soluble compounds that eliminate ammonia and
glutamate through the urine as phenylacetylglutamine.
Sodium
phenylacetate*
Crystalline
powder
Not applicable Forms water soluble compounds that eliminate ammonia through the
urine as phenylacetylglutamine.
Polyethylene
glycol
Electrolyte
solution
Administered at a
dose of four litre
orally or via a
nasogastric tube
A cathartic agent, which changes the bacterial flora in the gut thereby
reducing the uptake of ammonia.
Footnotes
*Include relatively high amounts of sodium.
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1 Search strategy
Database Time span Search terms
The Cochrane Hepato-
Biliary Group Controlled
Trials Register
Date to be
given at
review
stage.
(glycerol phenylbutyrat* or ravicti or ornithine phenylacetat* or OCR-002 or
(ammoni* and scaveng*)) AND (encephalopath* or liver disease* or cirrho*)
Cochrane Central
Register of Controlled
Trials (CENTRAL)
(Cochrane Library)
Latest issue. #1 glycerol phenylbutyrat* or ravicti or ornithine phenylacetat* or OCR-002 or
(ammoni* and scaveng*)
#2 MeSH descriptor: [Hepatic Encephalopathy] explode all trees
#3 MeSH descriptor: [Liver Diseases] explode all trees
#4 MeSH descriptor: [Fibrosis] explode all trees
#5 (encephalopath* or liver disease* or cirrho*)
#6 #2 or #3 or #4 or #5
#7 #1 and #6
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Database Time span Search terms
MEDLINE (Ovid SP) 1946 to the
date of
search.
1. (glycerol phenylbutyrat* or ravicti or ornithine phenylacetat* or OCR-002 or
(ammoni* and scaveng*)).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier]
2. exp Hepatic Encephalopathy/
3. exp Liver Diseases/
4. exp Fibrosis/
5. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique
identifier]
6. 2 or 3 or 4 or 5
7. 1 and 6
8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original
title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary concept word,
unique identifier]
9. 7 and 8
Embase (Ovid SP) 1974 to the
date of
search.
1. (glycerol phenylbutyrat* or ravicti or ornithine phenylacetat* or OCR-002 or
(ammoni* and scaveng*)).mp. [mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword]
2. exp hepatic encephalopathy/
3. exp liver disease/
4. exp fibrosis/
5. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, abstract, heading
word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword]
6. 2 or 3 or 4 or 5
7. 1 and 6
8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading
word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword]
9. 7 and 8
Science Citation Index
Expanded (Web of
Science)
1900 to the
date of
search.
#5 #4 AND #3
#4 TS=(random* or blind* or placebo* or meta-analys*)
#3 #2 AND #1
#2 TS=(encephalopath* or liver disease* or cirrho*)
#1 TS=(glycerol phenylbutyrat* or ravicti or ornithine phenylacetat* or OCR-002 or
(ammoni* and scaveng*))
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